FDA Publishes Draft Guidance on Assessment of DNA Reactive Impurities in Pharmaceuticals

Summary

The FDA has released a draft guidance document outlining the application of the ICH M7 guideline to calculate compound-specific acceptable intakes for DNA reactive impurities, which could impact the assessment of carcinogenic risk in pharmaceuticals.